EP1499343A4 - Verfahren zur modulierung der zellaktivität - Google Patents

Verfahren zur modulierung der zellaktivität

Info

Publication number
EP1499343A4
EP1499343A4 EP03745226A EP03745226A EP1499343A4 EP 1499343 A4 EP1499343 A4 EP 1499343A4 EP 03745226 A EP03745226 A EP 03745226A EP 03745226 A EP03745226 A EP 03745226A EP 1499343 A4 EP1499343 A4 EP 1499343A4
Authority
EP
European Patent Office
Prior art keywords
cellular activity
modulating cellular
modulating
activity
cellular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03745226A
Other languages
English (en)
French (fr)
Other versions
EP1499343A1 (de
Inventor
Stuart M Pitson
Pu Xia
Paul A Moretti
Julia R Zebol
Mathew A Vadas
Brian W Wattenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medvet Science Pty Ltd
Original Assignee
Medvet Science Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPS1448A external-priority patent/AUPS144802A0/en
Priority claimed from AUPS1538A external-priority patent/AUPS153802A0/en
Priority claimed from AUPS1621A external-priority patent/AUPS162102A0/en
Priority claimed from AU2002951668A external-priority patent/AU2002951668A0/en
Priority claimed from AU2003900230A external-priority patent/AU2003900230A0/en
Application filed by Medvet Science Pty Ltd filed Critical Medvet Science Pty Ltd
Publication of EP1499343A1 publication Critical patent/EP1499343A1/de
Publication of EP1499343A4 publication Critical patent/EP1499343A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
EP03745226A 2002-03-28 2003-03-28 Verfahren zur modulierung der zellaktivität Withdrawn EP1499343A4 (de)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
AUPS1448A AUPS144802A0 (en) 2002-03-28 2002-03-28 A method of modulating cellular activity
AUPS144802 2002-03-28
AUPS1538A AUPS153802A0 (en) 2002-04-05 2002-04-05 A method of modulating cellular activity - ii
AUPS153802 2002-04-05
AUPS1621A AUPS162102A0 (en) 2002-04-08 2002-04-08 A method of modulating cellular activity - III
AUPS162102 2002-04-08
AU2002951668A AU2002951668A0 (en) 2002-09-19 2002-09-19 A method of modulating cellular activity- IV"
AU2002951668 2002-09-19
AU2003900230A AU2003900230A0 (en) 2003-01-21 2003-01-21 "A method of modulating cellular activity - V"
AU2003900230 2003-01-21
PCT/AU2003/000388 WO2003082322A1 (en) 2002-03-28 2003-03-28 A method of modulating cellular activity

Publications (2)

Publication Number Publication Date
EP1499343A1 EP1499343A1 (de) 2005-01-26
EP1499343A4 true EP1499343A4 (de) 2005-12-28

Family

ID=28679096

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03745226A Withdrawn EP1499343A4 (de) 2002-03-28 2003-03-28 Verfahren zur modulierung der zellaktivität

Country Status (5)

Country Link
EP (1) EP1499343A4 (de)
JP (1) JP2005526809A (de)
AU (2) AU2003215426A1 (de)
CA (1) CA2480661A1 (de)
WO (1) WO2003082322A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005253643B2 (en) * 2004-06-15 2011-12-01 Medvet Science Pty. Ltd. Methods of modulating cellular activity involving sphingosine kinase and agents for same, and sphingosine kinase variants
MXPA06014888A (es) * 2004-06-15 2007-03-21 Medvet Science Pty Ltd Metodos para modular actividad celular que involucra esfingosina cinasa y agentes para los mismos, y variantes de esfingosina cinasa.
US8324237B2 (en) * 2005-05-20 2012-12-04 Smith Charles D Methods for the treatment and prevention of inflammatory diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU688355B2 (en) * 1993-07-20 1998-03-12 Regents Of The University Of California, The Regulation of transcription factor, NF-IL6/LAP
AUPO900297A0 (en) * 1997-09-08 1997-10-02 Medvet Science Pty. Ltd. A method of modulating cellular activity
CA2280675A1 (en) * 1998-08-26 2000-02-26 Nehama I. Smorodinsky Enhanced phosphorylation of p53 by atm in response to dna damage
ATE323153T1 (de) * 1999-05-13 2006-04-15 Johnson & Johnson Pharm Res Sphingosinekinase
CA2373814A1 (en) * 1999-05-28 2001-02-15 Apoptosis Technology, Inc. Compounds and methods for regulating apoptosis, and methods of making and screening for compounds that regulate apoptosis
AU2001241710B2 (en) * 2000-02-25 2005-07-21 The Regents Of The University Of California Membrane estrogen receptor-directed therapy in breast cancer
AUPQ744700A0 (en) * 2000-05-11 2000-06-01 Medvet Science Pty. Ltd. A method of treatment and agents useful for same
NZ529983A (en) * 2001-06-07 2006-09-29 Medvet Science Pty Ltd Sphingosine kinase interacts with TRAF2 and modulates tumor necrosis factor-induced cellular activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *

Also Published As

Publication number Publication date
EP1499343A1 (de) 2005-01-26
AU2009201639A1 (en) 2009-05-21
WO2003082322A1 (en) 2003-10-09
CA2480661A1 (en) 2003-10-09
JP2005526809A (ja) 2005-09-08
AU2003215426A1 (en) 2003-10-13

Similar Documents

Publication Publication Date Title
AU2002367739A1 (en) Activity management method
GB2386510B (en) Method of automatically altering the behaviour of a wireless information device
GB0223498D0 (en) Provision of information regarding a mobile station
GB2389179B (en) A method of electrophoresis
AU2003297700A8 (en) Methods for modulating ikkalpha activity
AU2003217416A1 (en) Method for extending the coverage area of a wireless communication
GB0319361D0 (en) A method of and system for wireless communication
EP1488046A4 (de) Bauverfahren
EP1512783A4 (de) Strickverfahren
GB2405555B (en) A cellular communication system and method of operation therefor
AU2002951253A0 (en) A method of modulating cellular activity
GB2389252B (en) A frequency modulation system & method
GB2408654B (en) A cellular communication system and a method of operation therefor
AUPS144802A0 (en) A method of modulating cellular activity
AU2002258036A8 (en) A method of making salt
AU2003264183A8 (en) A method of modulating cellular development
GB0204227D0 (en) Modulation of pde11a activity
AUPS162102A0 (en) A method of modulating cellular activity - III
AUPS153802A0 (en) A method of modulating cellular activity - ii
AU2002951212A0 (en) A method of modulating cellular activity and molecules for use therein
GB0219170D0 (en) Wireless communication system and a method of operating a wireless communication system
AU2004903249A0 (en) A method of modulating cellular activity and agents useful for same
GB2408431B (en) A wireless communication system and a method of operating a wireless communication system
AU2002951668A0 (en) A method of modulating cellular activity- IV"
GB0209145D0 (en) A set of steps

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20041028

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

RIN1 Information on inventor provided before grant (corrected)

Inventor name: WATTENBERG, BRIAN W.

Inventor name: VADAS, MATHEW A.

Inventor name: ZEBOL, JULIA R.

Inventor name: MORETTI, PAUL, A.

Inventor name: XIA, PU

Inventor name: PITSON, STUART M.

A4 Supplementary search report drawn up and despatched

Effective date: 20051110

17Q First examination report despatched

Effective date: 20071116

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20101001